United Health Products Business Summary

United Health Products, Inc. (UEEC) is a medical technology company that generates revenue through the development, manufacturing, and marketing of its proprietary hemostatic gauze, HemoStyp (also branded as CelluSTAT). The company's business model is centered on the commercialization of its patented Neutralized Oxidized Regenerated Cellulose (NORC) technology, an all-natural, hypoallergenic agent that converts to a gel to control bleeding. UEEC operates across three primary commercial segments: dental, veterinary, and emergency medicine (EMS), while aggressively pursuing a high-growth fourth segment in the human surgical market. As of early 2026, the company is focused on resolving FDA regulatory milestones to initiate supplemental clinical studies for Class III Premarket Approval (PMA). UEEC competes directly with industry giants such as Ethicon (a subsidiary of Johnson & Johnson), Baxter International, and Pfizer, as well as smaller peers like NEXGEL, Inc. and TELA Bio, Inc. Relative to these competitors, UEEC positions itself as a specialized, pure-play innovator offering a fully absorbable, plant-based alternative to traditional thrombin or collagen-based hemostats. The leadership team is led by Brian Thom, who serves as Chairman and Chief Executive Officer. Thom joined the company in late 2020, bringing over 20 years of corporate finance and M&A expertise from senior roles at JPMorgan and as a Managing Director at Société Générale. He is supported by Chief Financial Officer Kris Heaton, a CPA with two decades of experience at KPMG and Merrill Lynch, and Chief Medical Officer Dr. Gerald Abate, who oversees clinical strategy and regulatory engagement. Other key executives include John Phillips, Vice President of Commercial Strategy & Business Development, and Louis Schiliro, Director of Operations. The board of directors includes independent director Robert J. Denser, who provides extensive experience in federal medical procurement and disaster response. Notable institutional and insider interest is highlighted by significant holdings from co-founder Douglas Beplate and major shareholder Suzanna Kolb, reflecting a concentrated ownership structure focused on the long-term commercialization of the NORC platform.